Canada · Delayed Price · Currency is CAD Medicenna Therapeutics Statistics
Total Valuation
TSX:MDNA has a market cap or net worth of CAD 36.46 million. The enterprise value is 30.33 million.
| Market Cap | 36.46M |
| Enterprise Value | 30.33M |
Important Dates
The next estimated earnings date is Friday, July 10, 2026.
| Earnings Date | Jul 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TSX:MDNA has 92.30 million shares outstanding. The number of shares has increased by 8.51% in one year.
| Current Share Class | 92.30M |
| Shares Outstanding | 92.30M |
| Shares Change (YoY) | +8.51% |
| Shares Change (QoQ) | +0.00% |
| Owned by Insiders (%) | 13.25% |
| Owned by Institutions (%) | n/a |
| Float | 74.57M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 14.69 |
| P/TBV Ratio | 14.97 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.52, with a Debt / Equity ratio of 0.05.
| Current Ratio | 1.52 |
| Quick Ratio | 1.39 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -170.64% and return on invested capital (ROIC) is -128.16%.
| Return on Equity (ROE) | -170.64% |
| Return on Assets (ROA) | -76.07% |
| Return on Invested Capital (ROIC) | -128.16% |
| Return on Capital Employed (ROCE) | -749.98% |
| Weighted Average Cost of Capital (WACC) | 14.61% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -1.23M |
| Employee Count | 15 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -54.60% in the last 52 weeks. The beta is 1.89, so TSX:MDNA's price volatility has been higher than the market average.
| Beta (5Y) | 1.89 |
| 52-Week Price Change | -54.60% |
| 50-Day Moving Average | 0.49 |
| 200-Day Moving Average | 0.88 |
| Relative Strength Index (RSI) | 38.86 |
| Average Volume (20 Days) | 65,961 |
Short Selling Information
The latest short interest is 222,810, so 0.29% of the outstanding shares have been sold short.
| Short Interest | 222,810 |
| Short Previous Month | 150,128 |
| Short % of Shares Out | 0.29% |
| Short % of Float | 0.45% |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -22.42M |
| Pretax Income | -18.41M |
| Net Income | -18.41M |
| EBITDA | -22.40M |
| EBIT | -22.42M |
| Earnings Per Share (EPS) | -0.22 |
Balance Sheet
The company has 6.25 million in cash and 119,000 in debt, with a net cash position of 6.13 million or 0.07 per share.
| Cash & Cash Equivalents | 6.25M |
| Total Debt | 119,000 |
| Net Cash | 6.13M |
| Net Cash Per Share | 0.07 |
| Equity (Book Value) | 2.48M |
| Book Value Per Share | 0.03 |
| Working Capital | 2.85M |
Cash Flow
| Operating Cash Flow | -17.92M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 19,000 |
| Net Borrowing | -71,000 |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TSX:MDNA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.51% |
| Shareholder Yield | -8.51% |
| Earnings Yield | -50.49% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for TSX:MDNA is 2.80, which is 636.84% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 2.80 |
| Price Target Difference | 636.84% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
The last stock split was on March 3, 2017. It was a reverse split with a ratio of 0.0714285.
| Last Split Date | Mar 3, 2017 |
| Split Type | Reverse |
| Split Ratio | 0.0714285 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |